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Pediatric patients with multi-organ dysfunction syndrome re-
ceiving continuous renal replacement therapy.
Background. Critical illness leading to multi-organ dysfunc-
tion syndrome (MODS) and associated acute renal failure
(ARF) is less common in children compared to adult patients.
As a result, many issues plague the pediatric ARF outcome lit-
erature, including a relative lack of prospective study, a lack of
modality stratification in subject populations and inconsistent
controls for patient illness severity in outcome analysis.
Methods. We now report data from the first multicenter study
to assess the outcome of pediatric patients with MODS re-
ceiving continuous renal replacement therapy (CRRT). One
hundred twenty of 157 Registry patients (63 male/57 female)
experienced MODS during their course.
Results. One hundred sixteen patients had complete data
available for analysis. The most common causes leading to
CRRT were sepsis (N = 47; 39.2%) and cardiogenic shock (N =
24; 20%). Overall survival was 51.7%. Pediatric Risk of Mortal-
ity (PRISM 2) score, central venous pressure (CVP), and% fluid
overload (%FO) at CRRT initiation were significantly lower for
survivors versus nonsurvivors. Multivariate analysis controlling
for severity of illness using PRISM 2 at CRRT initiation re-
vealed that%FO was still significantly lower for survivors versus
nonsurvivors (P < 0.05) even for patients receiving both me-
chanical ventilation and vasoactive pressors. We speculate that
increased fluid administration from PICU admission to CRRT
initiation is an independent risk factor for mortality in pediatric
patients with MODS receiving CRRT.
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Conclusion. We suggest that after initial resuscitative efforts,
an increased emphasis should be placed on early initiation of
CRRT and inotropic agent use over fluid administration to
maintain acceptable blood pressure.
Advancements and improvements in care for critically
ill neonates, infants with congenital cardiac disease, and
children with sepsis, bone marrow and solid organ trans-
plantation have lead to a dramatic broadening of pe-
diatric acute renal failure (ARF) epidemiology [1–3].
Transition from the use of adaptive continuous renal
replacement therapy (CRRT) equipment to dedicated
hemofiltration machines with more precise volumet-
ric control [4] engendered a change in pediatric renal
replacement therapy modality prevalence patterns for
critically ill children, as surveys of U.S. pediatric nephrol-
ogists demonstrate increased CRRT use over the past five
years as the preferred modality for treating critically ill
pediatric patients with ARF [5, 6].
Critical illness leading to multi-organ dysfunction syn-
drome (MODS) and associated ARF is less common in
children compared to adult patients. As a result, many is-
sues plague the pediatric ARF outcome literature, includ-
ing a relative lack of prospective study, a lack of modality
stratification in subject populations, and the inconsistent
controls for patient illness severity in outcome analysis
[7–9]. A previous single-center pediatric study suggested
increased volume overload status at CRRT initiation was
associated with mortality, irrespective of severity of ill-
ness as measured by Pediatric Risk of Mortality (PRISM
2) score [10]. Other pediatric studies that do not assess
severity of illness with a scoring system suggest that
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increased inotropic agent requirement is associated with
mortality [1, 11].
We now report data from the first multicenter study to
assess the outcome of pediatric patients with MODS re-
ceiving CRRT. The present study aims to assess for poten-
tial associations between multiple clinical variables and
survival in this critically ill pediatric population.
METHODS
The Prospective Pediatric Continuous Renal Replace-
ment Therapy (ppCRRT) Registry Group is a multicen-
ter collaborative effort to evaluate various clinical and
therapeutic aspects of pediatric CRRT. The ppCRRT
Registry Group is currently designed in a prospective ob-
servational format; all centers practice according to local
standard of care, and have agreed to collect the same
data. The decisions to initiate, alter and terminate CRRT
are made by the Principal Investigator and/or colleagues
at the local institution; the ppCRRT Registry does not
direct any aspect of patient care. The current analysis
comprises data collected between 1/1/2001 and 8/31/2003
from seven United States pediatric centers with at least
10 patients enrolled: Texas Children’s Hospital/Baylor
College of Medicine (Houston, TX), The Children’s
Hospital (Boston, MA), Children’s Hospital & Regional
Medical Center (Seattle, WA), C.S. Mott Children’s Hos-
pital (Ann Arbor, MI), University of Alabama Children’s
Hospital (Birmingham, AL), Children’s Mercy Hospital
and Clinics (Kansas City, MO), and Children’s Health-
care of Atlanta at Egleston (Atlanta, GA). The Institu-
tional Review Board for each center approved the study
before patient enrollment.
Subject population and data collected
The ppCRRT Registry data are divided into three com-
ponents: pre-CRRT initiation data, pediatric intensive
care unit (PICU) data, and filter data. All subject records
are encoded with a unique identifier that corresponds to
the center and respective patient number. Data are trans-
mitted using each center’s password-protected database
and incorporated into the main database at Baylor Col-
lege of Medicine/Texas Children’s Hospital, Houston,
Texas.
For the present study, only data from subjects with
MODS were analyzed. A subject was defined as having
MODS if the underlying primary disease process leading
to ARF affected at least one organ system other than the
kidneys. Patient data were only collected once the local
center’s investigator obtained informed consent from the
subject’s parent or legal guardian.
Pre-CRRT initiation data collected were comprised of
the following: gender, age (years), primary disease lead-
ing to CRRT initiation, relevant comorbid illnesses, rea-
son for CRRT initiation (development of or prevention
of fluid overload, electrolyte imbalance, or both), days in
PICU until CRRT initiation, height (cm), PICU admis-
sion weight (kg), urine output in 24 hours before CRRT
initiation (mL/kg/hr), fluid input from PICU admission
to CRRT initiation (Fluid In; L), fluid out (urine, stool,
chest tube, etc.) from PICU admission to CRRT initia-
tion (Fluid Out; L), serum creatinine at PICU admission
and CRRT initiation (mg/dL), and blood urea nitrogen
at CRRT initiation (BUN; mg/dL). From these data, the
degree of fluid overload at CRRT initiation (%FO) was
calculated using the following formula [10]:
%FO = (Fluid In − Fluid Out)/
(PICU admission weight) × 100%.
Patient GFR at CRRT initiation was calculated using
the Schwartz formula [12].
PICU data collected were comprised of the following:
PRISM 2 score [13] at PICU admission and CRRT initi-
ation, central venous pressure at CRRT initiation (CVP,
mm Hg), inotropic agent number at CRRT initiation, in-
otropic medications used and their initial and maximum
doses, inotropic medications weaned off (yes/no), diuretic
use (yes/no), and mechanical ventilation mean airway
pressure (Paw) at CRRT initiation and termination. The
PRISM 2 score assesses 14 clinical variables from five dif-
ferent organ domains: cardiovascular (SBP, DBP, pulse),
respiratory (Resp rate, pO2, pCO2), neurologic (Glasgow
Coma score, pupillary reaction), hepatic (bilirubin), and
metabolic (potassium, calcium, total CO2, glucose).
Filter data collected comprised the following: CRRT
machine brand, anticoagulation method, priming solu-
tion, blood pump flow rate, dialysis/replacement solution
composition and flow rates, hemofiltration/hemodialysis/
hemodiafiltration rates, caloric (kcal/kg/day) and pro-
tein (g/kg/day) administration rates, circuit functional life
(hours), and reasons to terminate a circuit [scheduled
change, access malfunction, machine malfunction, unre-
lated patient reason (e.g., to take a patient to CT scan),
clotting, or modality change]. In addition, at the end of
each filter lifespan, each patient was assessed for attain-
ment of dry weight by physical exam. Reasons to termi-
nate CRRT were: patient death/withdrawal of support,
tolerates intermittent hemodialysis, inability to perform
CRRT, or regained renal function.
The predominant CRRT modality prescribed [con-
tinuous venovenous hemofiltration (CVVH), continu-
ous venovenous hemodialysis (CVVHD), and contin-
uous venovenous hemodiafiltration (CVVHDF)] was
recorded by each center for their patients. While all pa-
tients received some convective component of clearance
as a result the ultrafiltration of excessive fluid, and we
report total clearance in terms of the sum of the convec-
tive and diffusive clearance for all patients, we opted to
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conform to the accepted convention of defining modality
in terms of the use of replacement fluid alone (CVVH),
countercurrent dialysis fluid for diffusional clearance
without replacement fluid (CVVHD), or both dialysis
fluid and replacement fluid (CVVDHF). Analysis of
the convective contribution of ultrafiltration to clear-
ance to patients receiving CVVHD revealed a mean
relative contribution of 17.6 ± 9.0% (median 17.8%);
thus, for primarily diffusion-based CVVHD, less than one
fifth of clearance resulted from ultrafiltration-associated
convection.
Each center’s investigator initially characterized the
primary illness leading to CRRT use for each of its own
subjects. At the time of data analysis, the ppCRRT prin-
cipal investigator (S.L.G.) reviewed all subjects’ primary
illness designation and, from these, created a standard
definition set of primary illnesses. Each patient was as-
signed to one primary illness category based on the stan-
dard definition set. The standard definition set and each
patient’s assignment was reviewed by each center PI and
either approved, or an amendment was made based on
the recommendation of the center PI. A center PI reas-
signed only one patient after review.
The primary outcome measure was survival to PICU
discharge. The secondary outcome measure was attain-
ment of subject dry weight during the CRRT course (i.e.,
was the patient euvolemic at some point during the CRRT
course), irrespective of ultimate patient survival.
Statistical analysis
Potential association between various clinical variables
and patient survival was assessed by independent t test.
Multiple regression analysis using PRISM 2 score to con-
trol for severity of illness on subject survival was per-
formed for those variables demonstrating an association
with survival by t test. In addition, in order to further
control for illness severity in the most ill patients, a sub-
group multiple regression analysis was performed for
those patients receiving both mechanical ventilation (as
a surrogate of respiratory failure) and vasoactive pres-
sors (as a surrogate for cardiovascular compromise); thus,
in this manner, patients with three-organ involvement
were analyzed. Nonparametric analysis was performed
to assess for potential effects of <20% FO versus >20%
FO, and attainment of dry weight upon survival rates.
One-way analysis of variance was used to assess for po-
tential associations between survival rates and inotropic
agent number. Since a well-designed adult study demon-
strated increased survival with CVVH clearances >35
mL/kg/hr (approximately 2000 mL/hour/1.73 m2) [14],
we assessed for an association between CRRT clearance
<2000 mL/hour/1.73 m2 versus >2000 mL/hour/1.73 m2
and survival. A P value < 0.05 was considered significant.
Table 1. Demographic and clinical data at PICU admission and
CRRT initiation
Mean ± SD Median (range)
Age years 8.5 ± 6.8 7.2 (1 day to 25.1 years)
PICU admit weight kg 11.1 ± 25.5 25 (1.8 to 107.8)
PICU admit PRISM 2 15.4 ± 9.0 14 (0 to 45)
Days in PICU to CRRT Init 7.3 ± 14.1 3 (0 to 103)
CRRT Init GFR 38.8 ± 32.2 28.4 (1.4 to 150)
mL/min/1.73 m2
CRRT Init PRISM 2 16.4 ± 7.7 15 (0 to 38)
CRRT Init %FO % 17.4 ± 17.9 13.4 (−6.4 to 72.3)
CRRT Init inotrope number 1.5 ± 1.1 2 (0 to 5)
Abbreviations are: CRRT Init, CRRT initiation; PRISM 2, Pediatric Risk of
Mortality Score; %FO, percent fluid overload.
RESULTS
Demographic data
At the time of study analysis, 157 patients were entered
into the ppCRRT Registry and received a total of 20,062
hours of CRRT. One hundred twenty of 157 patients
(63 male/57 female) experienced MODS during their
course and comprised the cohort for the present
study.
Demographic data for patients with MODS are listed in
Table 1. The geographic distribution for the cohort is: 36
patients from Texas Children’s Hospital/Baylor College
of Medicine (26.7%), 23 from C.S. Mott Children’s Hos-
pital (19.2%), 20 from The Children’s Hospital, Boston
(16.7%), 20 from University of Alabama Children’s Hos-
pital (16.7%), 12 from Children’s Hospital & Regional
Medical Center (10%), 10 from Children’s Healthcare
of Atlanta at Egleston (8.3%) and three from Children’s
Mercy Hospital and Clinics (2.5%). The primary reasons
for CRRT initiation were treatment of fluid overload and
electrolyte imbalance (N = 65; 54.1%), treatment of fluid
overload only (N = 35; 29.2%), treatment of electrolyte
imbalance (N = 10; 8.3%), prevention of fluid overload
or electrolyte imbalance (N = 6; 5.0%), and other reasons
(N = 4; 3.3%).
The most common causes leading to CRRT were sep-
sis (N = 47; 39.2%) and cardiogenic shock (N = 24;
20%). The most common comorbid underlying illnesses
included bone marrow transplant (BMT) in 18 patients
and solid organ transplants in eight patients (6 liver, 2
heart). Eight patients had no cause other than MODS
identified as leading to need for CRRT.
One hundred of 120 patients (83.3%) were receiving
mechanical ventilation, and 53/120 patients (44.1%) were
receiving diuretics at the time of CRRT initiation.
Outcome data
Complete outcome data were available for 116/120
patients with MODS. Sixty patients survived (51.7%),
and 56 patients did not survive to discharge from the
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Table 2. Clinical variables and outcome
Variablea Survivors Nonsurvivors P value
Patient age years 8.49 ± 6.74 8.51 ± 7.19 NS
Patient weight kg 34.2 ± 25.4 31.7 ± 25.8 NS
PICU days to CRRTInit 6.5 ± 14.2 8.1 ± 14.0 NS
PRISM 2 at PICU admit 14.3 ± 8.2 16.2 ± 9.7 NS
PRISM 2 at CRRTInit 13.9 ± 8.2 18.6 ± 7.2 <0.003
CVP at CRRT Init mmH2O 16.5 ± 6.1 21.2 ± 6.6 <0.003
Intropes at CRRT Init 1.4 ± 1.1 1.7 ± 1.1 NS
Paw at CRRT Init mmH2O 16.9 ± 7.5 19.5 ± 10.0 NS
GFR at CRRT Init 36.3 ± 32.2 41.4 ± 32.2 NS
mL/min/1.73 m2
BUN at CRRT Init mg/dL 61.1 ± 41.8 67.8 ± 45.7 NS
%FO at CRRT Init 14.2 ± 15.9 25.4 ± 32.9 <0.03
CRRT clearance mL/hr/1.73 m2 1680 ± 994 1774 ± 1340 NS
Urine output mL/kg/hour 0.93 ± 1.3 0.92 ± 1.1 NS
aValues expressed as mean ± SD.
PICU. Survival rates were not statistically different be-
tween units with more than 10 complete outcome data
sets (range 40% to 50%). For the most common primary
causes leading to CRRT, survival rates were as follows:
sepsis (61%) and cardiogenic shock (53%); patients with
BMT or with hepatic dysfunction had a 33% survival rate.
Table 2 lists data comparing clinical variables for sur-
vivors versus nonsurvivors. Days from PICU admission
to CRRT initiation, patient age, weight, PRISM 2 score
at PICU admission, and inotrope number, GFR, urine
output, and BUN level at CRRT initiation were no differ-
ent for survivors compared to nonsurvivors. In contrast,
PRISM 2 score, central venous pressure (CVP), and%FO
at CRRT initiation were significantly lower for survivors
versus nonsurvivors. Paw at CRRT initiation was some-
what higher, and improvement in Paw (i.e., decrease in
Paw) over the course of CRRT was significantly better
for survivors (−6.6 ± 8.7 mmH2O) compared to non-
survivors (−0.5 ± 12.3 mmH2O; P < 0.05). Multivariate
analysis controlling for severity of illness using PRISM
2 at CRRT initiation for the entire cohort revealed that
CVP and%FO were still significantly lower for survivors
versus nonsurvivors (P < 0.05).
Seventy-six patients received both mechanical ventila-
tion and inotropic agents at CRRT initiation, and 35 of
these patients (46%) survived. Multivariate analysis of
this cohort using PRISM 2 demonstrated that%FO was
still significantly lower for survivors versus nonsurvivors
in this subgroup analysis.
Survival rates were no different for patients receiving 1
(40% survival), 2 (55%), or ≥3 (45%) inotropic agents at
CRRT initiation. Survival rates were significantly better
for patients with <20% FO (58% survival) versus >20%
FO (40%) at CRRT initiation (P < 0.002), even though
PRISM 2 scores for patients with <20% FO versus >20%
FO were no different at PICU admission (14.3 ± 7.6 vs.
17.3 ± 10.3) or CRRT initiation (16.1 ± 8.1 vs. 17.0 ± 7.5).
Survival rates were also significantly better for patients
who were able to attain dry weight during their CRRT
course (76% survival) versus patients who did not return
to their dry weight during the CRRT course (36%; P <
0.001).
Eighty-eight patients received CRRT with an AN-
69 membrane, and 28 patients received CRRT with a
polysulfone membrane. Sixty-nine patients were treated
with a diffusion only–based CRRT modality (CVVHD),
35 patients were treated with only a convective modal-
ity (CVVH), and 12 patients were treated with a
combination of diffusion and convection (CVVHDF).
Patients receiving CVVHDF had lower PRISM 2 scores
at PICU admission (9.9 ± 4.6) versus patients receiv-
ing CVVH (14.1 ± 8.9) or CVVHD (17.2 ± 9.1) (P <
0.05). However, PRISM 2 scores,%FO, and CVP at
CRRT initiation were no different between the three
CRRT modalities. Patient survival did not differ sig-
nificantly between CRRT modalities [CVVH (58%),
CVVHD (44%), CVVHDF (58%)]. No association was
observed between CRRT clearance <2000 mL/hr/1.73 m2
versus >2000 mL/hr/1.73m2 and survival rates.
DISCUSSION
Data from the current study comprise the largest co-
hort reported to date detailing the PICU course and
outcome of critically ill children with MODS and ARF
receiving CRRT. We chose to study patients with MODS
in the current analysis because they represent the most
critically ill patients, and most pediatric centers use
CRRT as the initial RRT modality for children with ARF
[15].
Our data suggest that greater patient fluid overload at
the time of CRRT initiation is associated with decreased
survival in critically ill pediatric CRRT patients. Although
the present study was not designed to randomize patients
to differing degrees of %FO, which would be unethi-
cal, examination of other clinical variables during the
PICU course lends insight into the potential effect of fluid
overload on outcome. Interestingly, severity of illness as
measured by PRISM 2 score was no different between
survivors and nonsurvivors at PICU admission, yet was
significantly lower for survivors compared to nonsur-
vivors at CRRT initiation. In addition, CVP values were
significantly lower for survivors compared to nonsur-
vivors. We speculate that CRRT patients who receive
more fluid from PICU admission to CRRT initiation de-
velop higher CVPs with greater extravasation into the
pulmonary interstitium and other extravascular spaces.
Because CRRT survivors and nonsurvivors had similar
PRISM 2 scores at PICU admission, yet nonsurvivors had
higher PRISM 2 scores at CRRT initiation, we hypoth-
esize that increased fluid administration was associated
with an increased risk of mortality in this cohort.
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The present study findings strengthen preliminary con-
clusions reported in a previous small pediatric study [10].
The additional data examined herein led to observations
that nonsurvivors had higher %FO, demonstrated less
improvement in Paw during CRRT, and were less likely
to reattain their target dry weight. While physical exam-
ination is a crude assessment of dry weight and volume
status, patients with critical illness are often too unstable
to receive accurate weight measurements. Thus, resolu-
tion of peripheral and sacral edema, coupled with a de-
crease in Paw, may be reasonable indicators of decreased
fluid overload. These additional findings provide indica-
tions that prevention of excessive fluid overload may be
a hallmark of optimal care for the pediatric patient with
MODS and ARF.
Cautious interpretation of these ppCRRT Registry
data is warranted, and determining optimal fluid manage-
ment for critically ill children may be controversial. It is
certainly possible that increased%FO merely delineated
more critically ill patients who had exaggerated capil-
lary leak and required more fluid resuscitation to main-
tain cardiac output and end-organ perfusion. However,
controlling for severity of illness using PRISM 2 scores
for the entire cohort, and for patients with both respira-
tory and cardiovascular compromise, demonstrated that
lower%FO status remained an independent predictor of
survival.
We realize a potential criticism of our study is that
PRISM 2 score investigators did not intend for PRISM
2 to be used as a marker of severity of illness for any
time except PICU admission [13]. For this reason, we did
not attempt to predict patient survival using PRISM 2.
Rather, we employed PRISM 2 scores at PICU admission
and CRRT initiation as a surrogate for severity of illness.
A previous report shows PRISM 2 to be a poor predictor
of outcome in children with ARF [16], likely because the
PRISM 2 score does not directly account for renal func-
tion. Since no pediatric severity of illness scoring system
has been validated for children with ARF receiving re-
nal replacement therapy, and yet, controlling for patient
severity of illness is critical for outcome analysis, we at-
tempted to overcome PRISM 2 limitations by assessing
renal function with creatinine clearance and normalized
urine output at CRRT initiation—both of which were no
different between survivors and nonsurvivors.
We do not interpret our findings to advocate the with-
holding of fluid administration for critically ill children in
shock. Rather, we suggest that our data support a prac-
tice of goal-directed fluid therapy in this cohort, a concept
that has gained attention in adult patients. Fluid resusci-
tation in critically ill children is essential with appropri-
ate use in acute hypovolemic and septic shock states [17,
18]. The subacute effects of fluid overload, however, are
more uncertain. Several studies have suggested an asso-
ciation between excessive fluid retention and negative
patient outcome. Adult surgical ICU patients who de-
velop fluid retention have increased morbidity, increased
requirements for blood products, prolonged dependency
on pressors, and a two-fold increase in death [19]. Fluid
overload has also been associated with decreased survival
in adult patients with ARDS [20–22]. Use of strict fluid
restriction protocols was associated with fewer ventilator
and ICU days in one adult study [22].
CONCLUSION
A recent adult study [18] demonstrated that adult pa-
tients who received early goal-directed fluid therapy in
the emergency center received more fluid in the emer-
gency center, but received less fluid and had better sur-
vival in the ICU compared to patients who received
standard therapy. This adult study used a number of phys-
iologic end points to guide fluid resuscitation, including
mean arterial blood pressure and CVP, which can easily
be measured in pediatric patients. Our current observa-
tions that greater fluid overload and CVP were asso-
ciated with patient mortality, coupled with adult study
experience that goal-directed fluid resuscitation support
led to less post-resuscitation fluid administration and bet-
ter patient outcomes, supports development of a pedi-
atric practice that accounts for fluid administration in
critically ill patients. We suggest that after initial re-
suscitative efforts in critically ill children, an increased
emphasis should be placed on early initiation of CRRT
and inotropic agent use over fluid administration to main-
tain acceptable blood pressure. Ongoing assessment of
%FO using the simple formula presented in this study
may serve as an important parameter to evaluate patient
fluid overload status and guide the fluid management in
critically ill pediatric patients with ARF.
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